Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

e form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential for Zevalin FIT data to be acceptable to the FDA for this expanded indication or any other indication, the determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling Zevalin, and the ability of CTI to continue to raise capital to fund its operations. There is also a risk that even if label expansion of Zevalin is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources ... brought about by the Affordable Care Act ... prescribing of pharmaceutical therapies. The ACA altered ... through new regulations and expanded access via ... the health exchanges—state-based marketplaces set up by ...
(Date:7/31/2014)... LISBON, Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval ... The inspection, carried out by the FDA Consumer Safety ... initially planned, started on 21 st July and concluded ... to be compliant with the principles and guidelines of Good ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
(Date:8/1/2014)... Did you know that July was ... is to raise awareness across the country and to educate ... According to the American Cancer Society, nearly 5,000 Americans are ... new soft tissue sarcomas will be diagnosed. , “A ... they are other kinds of cancer,” said Dr. Chawla, a ...
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, “It ... newly released article entitled, “ 5 Signs That Your ... ,” Clean Crawls explains the need to replace insulation ... critters. , Get a free attic insulation or ... http://www.cleancrawl.com/contact . , If crawl space or attic insulation ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
(Date:8/1/2014)... 2014 The Multiple System Atrophy Coalition, a ... caregivers and families affected by the neurological disorder Multiple System ... La Coste, TX to its Board of Directors. , Sharon ... Eric Sutton. He was diagnosed officially with MSA in 2010 ... his family. Like many others with this rare disorder it ...
(Date:8/1/2014)... WA (PRWEB) August 01, 2014 Blindness is ... be argued that the scientists of today, despite well-meaning efforts, ... to providing a definite treatment for reversing blindness that does ... that sense, this is where alternative medicine takes the “slack” ... rely on expensive treatments or harmful surgeries. , Alternative ...
Breaking Medicine News(10 mins):Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2
... Cloning Livestock From,Differentiated Donor Cells, AUSTIN, Texas, ... that the U.S. Patent and Trademark Office has,granted ... of,cloning ungulate animals, fetuses and embryos using differentiated ... of patents and patent,applications owned by Roslin Institute ...
... N.C., Dec. 11 Quintiles,Transnational Corp. today announced ... and General Counsel., Previously Senior Vice President, ... in 1998 as Vice President, European,Legal Affairs., ... the clinical,research industry, having served the company in ...
... Brings More Than 30 Years Experience to ... Personal Therapeutic Device Leader, ... INCR) manufacturer of the RESPeRATE(R) hypertension treatment,device, clinically-proven to significantly ... Vice President of Sales. Dube,brings more than 30 years of ...
... WILLIAMSVILLE, N.Y., Dec. 11 The office of,Congressman ... Leadership,Award for voting against huge cuts in Medicare ... Reynolds received the award from The,Coalition for Medicare ... strengthen Medicare Choices., David Trumpfheller, Coalition Member ...
... Amedica Corporation, an,orthopedic implants company focused on silicon ... and Drug Administration,has granted a Special 510(k) marketing ... The Valeo VBR spinal implant is intended for ... stabilization of the thoracolumbar spine.,The Valeo VBR incorporates ...
... Valued at Over $96,000, LIVINGSTON, N.J., Dec. ... announced today that its wholly-owned,subsidiary, Genotec Nutritionals, Inc., ... sales from the distribution of its branded,products and ... closed on a large order for a new ...
Cached Medicine News:Health News:Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents 2Health News:InterCure Names Scot Dube Vice President of Sales 2Health News:InterCure Names Scot Dube Vice President of Sales 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:MM2 Group Closes Sale for New Fish Oil Product 2Health News:MM2 Group Closes Sale for New Fish Oil Product 3
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
... EDS 3 CSF External Drainage System was developed ... physicians. The clinicians who work every day with ... EDS 3: ease-of-use in an integrated pole clamp, ... accurate hydrostatic leveling from a unique laser leveling ...
... Trippi-Wells and Universal tongs were developed for ... than can be safely provided for with ... construction. Kit complete with four skull pins ... pin application. Skull pins at 10 angle. ...
Cruchfield Skull Traction Tong, small pattern....
Medicine Products: